0000000000476958

AUTHOR

C. Serra

showing 6 related works from this author

Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy

2019

Background: Influenza vaccines are updated every year to match the vaccine strains with currently circulating viruses; consequently influenza vaccine effectiveness (IVE) has to be assessed annually.Research design and methods: A test-negative case-control study was conducted within the context of the Italian sentinel influenza surveillance network to estimate IVE by age group, virus subtype, and vaccine brand in medically attended laboratory-confirmed influenza.Results: In Italy, the 2018/19 influenza season was characterized by the co-circulation of influenza A(H1N1)pdm09 and A(H3N2) viruses. The adjusted IVE estimate in preventing influenza was moderate (44.8%, 95% CI: 18.8 to 62.5) again…

Maletest-negative case-control study0301 basic medicinePrevalenceInfluenza vaccine effectiveness test-negative case-control study national influenza surveillance network ItalySettore MED/42 - Igiene Generale E ApplicataInfluenza A Virus H1N1 Subtype0302 clinical medicineDrug DiscoveryEpidemiology030212 general & internal medicineChildInfluenza vaccine effectivenessAged 80 and overnational influenza surveillance networkAge Factorsvirus diseasesMiddle Aged3. Good healthVaccinationTreatment OutcomeItalyInfluenza VaccinesChild PreschoolMolecular MedicineFemaleInfluenza vaccine effectiveness; Italy; national influenza surveillance network; test-negative case-control studyAdultmedicine.medical_specialtyAdolescentInfluenza vaccineImmunologyContext (language use)VirusYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineAnimalsHumansAgedPharmacologybusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyInfant030104 developmental biologyImmunizationCase-Control StudiesbusinessExpert Review of Vaccines
researchProduct

Metabolic disorders across hepatocellular carcinoma in Italy

2018

Background: Metabolic disorders are well-known risk factors for HCC. Conversely, their impact on the natural history of HCC is not established. This study aimed at evaluating the impact of metabolic disorders on clinical features, treatment and survival of HCC patients regardless of its aetiology. Methods: We analysed the ITA.LI.CA database regarding 839 HCC patients prospectively collected. The following metabolic features were analysed: BMI, diabetes, arterial hypertension, hypercholesterolaemia and hypertriglyceridaemia. According to these features, patients were divided into 3 groups: 0-1, 2 and 3-5 metabolic features. Results: As compared with patients with 0-1 metabolic features, pati…

OncologyMaleobesityDatabases FactualHepatocellular carcinoma0302 clinical medicineRisk FactorsProspective cohort studydiabetesMetabolic disorderLiver NeoplasmsDiabeteshepatocellular carcinomaMiddle AgedMetabolic syndromePortal vein thrombosisItaly030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemalemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIADiabetes; Hepatocellular carcinoma; Metabolic syndrome; Obesitymetabolic syndrome03 medical and health sciencesDatabasesMetabolic DiseasesInternal medicinemedicineDiabetes MellitusHumansObesityFactualAgedNeoplasm StagingRetrospective StudiesHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseaseSurvival AnalysisBCLC Stagediabetes; hepatocellular carcinoma; metabolic syndrome; obesity; Aged; Carcinoma Hepatocellular; Databases Factual; Diabetes Mellitus; Female; Humans; Italy; Liver Neoplasms; Male; Metabolic Diseases; Middle Aged; Multivariate Analysis; Neoplasm Staging; Obesity; Retrospective Studies; Risk Factors; Survival AnalysisdiabeteMultivariate AnalysisLiver functionMetabolic syndromebusiness
researchProduct

Correction to: Potentially modifiable factors contributing to outcome from acute respiratory distress syndrome: the LUNG SAFE study (Intensive Care M…

2018

The members of the LUNG SAFE Investigators and the ESICM Trials Group were provided in such a way that they could not be indexed as collaborators on PubMed. The publisher apologizes for this error.

Critical Care and Intensive Care Medicine
researchProduct

Resolved versus confirmed ARDS after 24 h: insights from the LUNG SAFE study

2018

Purpose: To evaluate patients with resolved versus confirmed ARDS, identify subgroups with substantial mortality risk, and to determine the utility of day 2 ARDS reclassification. Methods: Our primary objective, in this secondary LUNG SAFE analysis, was to compare outcome in patients with resolved versus confirmed ARDS after 24 h. Secondary objectives included identifying factors associated with ARDS persistence and mortality, and the utility of day 2 ARDS reclassification. Results: Of 2377 patients fulfilling the ARDS definition on the first day of ARDS (day 1) and receiving invasive mechanical ventilation, 503 (24%) no longer fulfilled the ARDS definition the next day, 52% of whom initial…

MaleARDSmedicine.medical_treatmentlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]ARDS reassessment; ARDS Survival; Berlin criteria ARDS; Persisting ARDS;Critical Care and Intensive Care Medicineassisted ventilation0302 clinical medicineRisk Factors030212 general & internal medicinerisk factor AdultTidal volumecomparative studyeducation.field_of_studyRespiratory Distress SyndromeMortality rateRemission Inductiontidal volumeARDS reassessment; ARDS Survival; Berlin criteria ARDS; Persisting ARDS; Critical Care and Intensive Care MedicineARDS reassessmentartificial ventilationclinical trialimmunosuppressive treatmentadult respiratory distress syndromeMiddle AgedARDS SurvivalMonte Carlo methodmedicine.anatomical_structureclassificationpositive end expiratory pressureCardiologyDisease ProgressionSOFA scoredisease severityFemaleAdultmedicine.medical_specialtyPopulationdisease classificationArticleNO03 medical and health sciencesremissionlength of stayAnesthesiologyInternal medicinemedicinepneumoniaSequential Organ Failure Assessment ScoreHumanshumaneducationAgedMechanical ventilationhospital mortalityLungbusiness.industryRisk Factordisease associationRespiratory Distress Syndrome AdultPersisting ARDSmedicine.diseasemajor clinical studymortalityRespiration Artificialbreathing rate030228 respiratory systemdisease exacerbationBerlin criteria ARDSbusinessIntensive care medicine
researchProduct

Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021

2022

Background Several SARS-CoV-2 variants of concern (VOC) have emerged through 2020 and 2021. There is need for tools to estimate the relative transmissibility of emerging variants of SARS-CoV-2 with respect to circulating strains. Aim We aimed to assess the prevalence of co-circulating VOC in Italy and estimate their relative transmissibility. Methods We conducted two genomic surveillance surveys on 18 February and 18 March 2021 across the whole Italian territory covering 3,243 clinical samples and developed a mathematical model that describes the dynamics of co-circulating strains. Results The Alpha variant was already dominant on 18 February in a majority of regions/autonomous provinces (…

EpidemiologySARS-CoV-2Public Health Environmental and Occupational HealthCOVID-19co-circulation; lineage; SARS-CoV-2 variant of concern; transmissibility; Humans; Italy; Models Theoretical; COVID-19; SARS-CoV-2Models TheoreticalSettore MED/42 - Igiene Generale E ApplicataSARS-CoV-2 variant of concern; co-circulation; lineage; transmissibility; Humans; Italy; Models Theoretical; COVID-19; SARS-CoV-2SARS-CoV-2 variant of concernSARS-COV-2 VARIANT OF CONCERN CO-CIRCULATION LINEAGE TRANSMISSIBILITY HUMANS ITALY MODELS THEORETICAL COVID-19 SARS-COV-2ItalyTheoreticalModelsVirologytransmissibilityHumansHumanco-circulationlineage
researchProduct

SIUMB guidelines and recommendations for the correct use of ultrasound in the management of patients with focal liver disease

2019

The present document describes the SIUMB (Italian Society of Ultrasound in Medicine and Biology) guidelines for the use of ultrasound in the management of focal liver disease. The aim of the paper is to provide a clinical practice guideline for Italian physicians who are approaching the ultrasound study of a focal liver lesion. In particular, these guidelines provide simple indications, recommendations and general practice advices for the correct use of contrast-enhanced ultrasound (CEUS) in this scenario. They represent the SIUMB position of the ultrasound role in the diagnostic flow charts of the principal focal liver lesions, and are in agreement with other, previously published national…

medicine.medical_specialtySettore MED/09 - Medicina InternaHepatocellular carcinomaContrast enhanced ultrasoundCholangiocellular carcinoma; Contrast enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular carcinoma; MetastasisContrast MediaMetastasiCholangiocellular carcinoma030218 nuclear medicine & medical imagingMetastasis03 medical and health sciencesLiver disease0302 clinical medicineFocal nodular hyperplasiaInternal MedicineHumansMedicineRadiology Nuclear Medicine and imagingMedical physicsUltrasonographyUltrasound studybusiness.industryLiver NeoplasmsUltrasoundFocal nodular hyperplasiaGeneral MedicineGuidelinemedicine.diseaseClinical PracticeLiverLiver lesionOriginal Article030211 gastroenterology & hepatologyCholangiocellular carcinoma; Contrast enhanced ultrasound; Focal nodular hyperplasia; Hemangioma; Hepatocellular carcinoma; Metastasis; Contrast Media; Humans; Liver; Liver Neoplasms; UltrasonographybusinessHemangiomaContrast-enhanced ultrasound
researchProduct